David Ricks, the chair and chief executive of Eli Lilly, speaking at The New York Times’s DealBook Summit, said his $750 ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.

Eli Lilly said Wednesday that its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in a head-to-head ...